High materiality7/10
Can-Fite BioPharma (CANF) PT Raised to $8 at H.C. Wainwright
Why it may matterVerify against the original reporting
Upside implied by higher PT; potential catalyst.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Analyst target updated; H.C. Wainwright lifts CANF price target to $8; current price $4.63.
- Target: $8; price: $4.63; firm: H.C. Wainwright.
Key facts
- 01
Target: $8
- 02
Posted price: $4.63
- 03
Analyst firm: H.C. Wainwright
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.